Recruitment

Recruitment Status
Active, not recruiting

Summary

Conditions
  • Lung Diseases, Interstitial
  • Vitamin D Deficiency
Type
Interventional
Phase
Not Applicable
Design
Allocation: RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: Arm 1(interventional group): interstitial lung diseases patients with vitamin D deficient / insufficient will receive Vitamin D supplementation and ca in addition to current treatment. Arm 2(control group): interstitial lung diseases patients with vitamin D deficient / insufficient will receive current treatment without vitamin D supplementationMasking: None (Open Label)Primary Purpose: Other

Participation Requirements

Age
Between 18 years and 75 years
Gender
Both males and females

Description

Pulmonary fibrosis was due to chronic inflammation and disordered wound healing in response to damage induced by a variety of agents such as viral infection and radiotherapy or environmental toxins.it is characterized by accumulation of myofibroblasts and excessive deposition of the extracellular ma...

Pulmonary fibrosis was due to chronic inflammation and disordered wound healing in response to damage induced by a variety of agents such as viral infection and radiotherapy or environmental toxins.it is characterized by accumulation of myofibroblasts and excessive deposition of the extracellular matrix.Epithelial cells undergoes epithelial mesenchymal transition (EMT). Supplementation with vitamin D or its analogs suppresses lung fibrosis via triggering anti-fibrotic effect through attenuation of transforming growth factor beta (TGF-B).vitamin D can reduce TGF-B expression and attenuate TGF-B induced epithelial mesenchymal transition in lung fibroblast and epithelial cells.

Tracking Information

NCT #
NCT04100226
Collaborators
  • Samah Selim Abdel Naiem Selim
  • Naglaa Bakry Ahmed Elkhatib
Investigators
Study Chair: Esmat Ai Ali, MD Professor of chest diseases,Faculty of Medicine, Cairo University